At SigutLabs, we continuously track emerging technologies that push the boundaries of antibody–drug conjugate (ADC) design. One innovation that has captured significant attention is the exo-cleavable linker architecture—an elegant solution addressing several long-standing challenges of conventional linker systems such as Val–Cit–PAB.

Why Exo-Cleavable Linkers Matter

Exo-cleavable linkers reposition the peptide sequence to an “exo” (outer) orientation. This seemingly simple shift delivers several important advantages:

• Improved plasma stability
  Designed to minimize premature payload release and maintain ADC integrity in circulation.

• Reduced aggregation
  Better performance even with hydrophobic payloads, leading to improved developability.

• More precise DAR control
  Supports higher drug loading without creating solubility or manufacturability issues.

• Controlled intracellular release
  Stable in the bloodstream yet efficiently cleaved within the target environment.

• Streamlined manufacturing
  Enhanced process consistency and robustness.

These benefits make exo-cleavable linkers an attractive option for next-generation ADC platforms focused on efficiency, safety, and scalability.

Our Work at SigutLabs

Our chemistry team actively develops and optimizes custom linker–payload systems, including designs inspired by exo-cleavable principles. We focus on:

• Tailoring linker polarity

• Adjusting cleavage-site accessibility

• Engineering payload attachment chemistry

• Enhancing overall stability and efficacy profiles

Our goal is to support ADC developers with well-characterized, high-performance linker systems that accelerate progress from concept to candidate.

Partner With Us

If your ADC program is exploring innovative linker architectures or requires bespoke linker–payload solutions, we would be happy to collaborate. Our synthesis and design capabilities can help bring the next generation of ADCs closer to clinical reality.

Let’s connect and advance your ADC platform together.